Pixantrone regulatory update

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 10 to discuss an NDA from Cell Therapeutics for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who ...